SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Drug Expenses
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Augustus Gloop who wrote (52)2/28/2003 11:59:39 AM
From: Biomaven  Read Replies (1) of 93
 
Synthroid is a very weird case - it wasn't even formally approved by the FDA until last year. Aside from some oddballs like Synthroid and Premarin, the vast majority of generics get very rapid acceptance and an overwhelming market shares. Just look at what happened to Lilly's Prozac sales when a generic was approved for a good example.

The big pharmas certainly have played games to try to delay generic competition, but virtually all of the funny games (new patent filings in the FDA Orange Book, payments to generic manufacturers) have now ceased.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News